Options for modulation of drug resistance in ovarian cancer

International Journal of Gynecological Cancer

Volumn 10, Issue SUPPL. 1, 2000, Pages 47-52

  Arts, H J G ^a   Van Der Zee, A G J ^a   De Jong, S ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Drug resistance; Ovarian cancer; Review

Indexed keywords

ANTHRACYCLINE; EPIPODOPHYLLOTOXIN DERIVATIVE; TAXANE DERIVATIVE;

APOPTOSIS; ARTICLE; DNA DAMAGE; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033994739     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.99511.x     Document Type: Article

References (41)

1. Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997; 349: 113-7.
2. Ozols RF, Vermorken JB. Chemotherapy of advanced ovarian carcinoma: current status and future directions. Semin Oncol 1997; 24: S2-1-S2-9.
3. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998; 25: 340-8.
4. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996; 32A: 912-20.
5. Izquierdo MA, van der Zee AG, Vermorken JB et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230-7.
6. Van der Zee AG, Hollema H, Suurmeijer AJ et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-8.
7. Rubin SC, Finstad CL, Hoskins WJ et al. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 1990; 163: 69-73.
8. Arts HJG, Katsaros D, deVries EG et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian cancer. Clin Cancer Res 1999; 5: 2789-805.
9. Sandor V, Fojo T, Bates SE. Future perspectives for the development of P- glycoprotein modulators. Drug Resistance Updates 1998; 1: 190-200.
10. Wood L, Palmer M, Hewitt J et al. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. Br J Cancer 1998; 77: 627-31.
11. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996; 32A: 945-57.
12. Borst P, Kool M, Evers R. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? Semin Cancer Biol 1997; 8: 205-13.
13. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-75.
14. Van der Zee AG, de Jong S, Keith WN, Hollema H, Boonstra H, de Vries EGE. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 1994; 54: 749-55.
15. Withoff S, van der Zee AG, de Jong S et al. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer. Br J Cancer 1999; 79: 748-53.
16. Van der Zee AG, Hollema HH, de Bruijn HW et al. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 1995; 58: 165-78.
17. Kool M, de Haas M, Scheffer GL et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance- associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57: 3537-47.
18. Koike K, Kawabe T, Tanaka T et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57: 5475-9.
19. Izquierdo MA, Scheffer GL, Flens MJ, Shoemaker RH, Rome LH, Scheper RJ. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anti-cancer drugs. Cytotechnology 1996; 19: 191-7.
20. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991; 64: 215-20.
21. O'Dwyer PJ, Hamilton TC, LaCreta FP et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients. J Clin Oncol 1996; 14: 249-56.
22. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84: 1512-7.
23. Mackean MJ, Millan D, Paul J, Kaye SB, Brown R. The clinical relavance of mismatch repair protein immunohistochemistry in ovarian cancer. Proc Am Assoc Cancer Res 1999 in press.
24. Bookman MA. Biological therapy of ovarian cancer: current directions. Semin Oncol 1998; 25: 381-96.
25. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9: 1829-38.
26. Van der Zee AG, Hollema H, de Jong S et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991; 51: 5915-20.
27. Bos AME, De Vries EGE, van der Zee AGJ et al. Phase I and pharmacokinetic study of intraperitoneal topotecan. Proc Am Assoc Clin Oncol 1999 in press.
28. Coukos G, Rubin SC. Chemotherapy resistance in ovarian carcinoma: new molecular perspectives. Obstet Gynecol 1998; 91: 783-92.
29. Hickman. Apoptosis and chemotherapy resistance. Eur J Cancer 1996; 32A: 921-6.
30. Levesque MA, Katsaros D, Yu H et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995; 75: 1327-38.
31. Wiman KG. New p53-based anti-cancer therapeutic strategies. Med Oncol 1998; 15: 222-8.
32. Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 1998; 4: 835-46.
33. Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nature Med 1998; 4: 1341-2.
34. Tai Y, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998; 16: 2583-90.
35. Marx D, Binder C, Meden H et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997; 17: 2233-40.
36. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998; 58: 2057-62.
37. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 1998; 101: 1102-10.
38. Ossina NK, Cannas A, Powers VC et al. Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997; 272: 16351-7.
39. Willemse PHB, de Vries EGE, Mulder NH, Aalders JG, Bouma J, Sleijfer DT. Intraperitoneal human recombinant Interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer 1990; 26: 353-8.
40. Rensing-Ehl A, Frei K, Flury R et al. Local Fas-APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995; 25: 2253-8.
41. Walczak H, Miller RE, Ariail K. Tumoricidal activity of tumor necrosis factor- related apoptosis-inducing ligand in vivo. Nature Med 1999; 5: 157-63.